Lihua Liu1, Diana J Moke2, Kai-Ya Tsai1, Amie Hwang1,3, David R Freyer2,3, Ann S Hamilton1, Juanjuan Zhang1, Myles Cockburn1,3,4, Dennis Deapen1,3. 1. Los Angeles Cancer Surveillance Program, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA. 2. Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA. 3. USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. 4. University of Colorado Comprehensive Cancer Center, University of Colorado, Denver, CO.
Abstract
BACKGROUND: Cancer survival among adolescents and young adults (AYAs) was previously reported as showing little or no improvement compared to younger or older counterparts. The role of the HIV/AIDS epidemic in the AYA survival deficit has not been evaluated. METHODS: Using cancer registry data from the Surveillance, Epidemiology, and End Results program (SEER 9), we examined sex-specific 5-year relative survival trends for children (0-14 years old), AYAs (15-39 years old), and older adults (40 years and older) diagnosed with cancer during 1973-2009 and followed through the end of 2014. The analysis was conducted with and without Kaposi sarcoma (KS) and lymphomas, and by two time periods: 1973-1977 (before the human immunodeficiency virus/acquired immunodeficiency syndrome [HIV/AIDS] epidemic) and 2005-2009 (after the HIV/AIDS epidemic waned). RESULTS: A total of 3 209 721 invasive cancer cases were included in the study (27 646 children, 213 930 AYAs, and 2 968 145 older adults; 24 803 children, 178 741 AYAs, and 2 844 062 older adults when KS and lymphoma cases were excluded). We found that 5-year relative survival for AYAs exceeded that of children and older adults before the onset of the HIV/AIDS epidemic (eg, during 1973-1979, 0.58-0.67 among male AYAs as compared with 0.47-0.61 for male children and 0.36-0.42 for male older adults; among female AYAs, the numbers were 0.73-0.77 as compared with 0.51-0.65 for female children and 0.52-0.55 for female older adults); substantially declined during 1983-1997 when HIV/AIDS lacked effective treatment among male AYAs; and returned to be higher than most age groups by the late 1990s after HIV/AIDS was controlled. Nonetheless, comparison of survival improvement between 1973-1977 and 2005-2009 demonstrated less progress in AYAs than other age groups, which was due to AYAs' better baseline survival and larger survival gains among children and older adults in recent years. CONCLUSIONS: Apart from the temporary impact of HIV/AIDS, survival among AYA cancer patients has shown sustained improvement and superiority relative to other age groups. However, these encouraging findings do not negate the distinctive challenges in cancer diagnosis, treatment, and survivorship faced by AYAs.
BACKGROUND:Cancer survival among adolescents and young adults (AYAs) was previously reported as showing little or no improvement compared to younger or older counterparts. The role of the HIV/AIDS epidemic in the AYA survival deficit has not been evaluated. METHODS: Using cancer registry data from the Surveillance, Epidemiology, and End Results program (SEER 9), we examined sex-specific 5-year relative survival trends for children (0-14 years old), AYAs (15-39 years old), and older adults (40 years and older) diagnosed with cancer during 1973-2009 and followed through the end of 2014. The analysis was conducted with and without Kaposi sarcoma (KS) and lymphomas, and by two time periods: 1973-1977 (before the human immunodeficiency virus/acquired immunodeficiency syndrome [HIV/AIDS] epidemic) and 2005-2009 (after the HIV/AIDS epidemic waned). RESULTS: A total of 3 209 721 invasive cancer cases were included in the study (27 646 children, 213 930 AYAs, and 2 968 145 older adults; 24 803 children, 178 741 AYAs, and 2 844 062 older adults when KS and lymphoma cases were excluded). We found that 5-year relative survival for AYAs exceeded that of children and older adults before the onset of the HIV/AIDS epidemic (eg, during 1973-1979, 0.58-0.67 among male AYAs as compared with 0.47-0.61 for male children and 0.36-0.42 for male older adults; among female AYAs, the numbers were 0.73-0.77 as compared with 0.51-0.65 for female children and 0.52-0.55 for female older adults); substantially declined during 1983-1997 when HIV/AIDS lacked effective treatment among male AYAs; and returned to be higher than most age groups by the late 1990s after HIV/AIDS was controlled. Nonetheless, comparison of survival improvement between 1973-1977 and 2005-2009 demonstrated less progress in AYAs than other age groups, which was due to AYAs' better baseline survival and larger survival gains among children and older adults in recent years. CONCLUSIONS: Apart from the temporary impact of HIV/AIDS, survival among AYA cancerpatients has shown sustained improvement and superiority relative to other age groups. However, these encouraging findings do not negate the distinctive challenges in cancer diagnosis, treatment, and survivorship faced by AYAs.
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: Archie Bleyer; Ronald Barr; Brandon Hayes-Lattin; David Thomas; Chad Ellis; Barry Anderson Journal: Nat Rev Cancer Date: 2008-04 Impact factor: 60.716
Authors: Theresa H M Keegan; Lynn A G Ries; Ronald D Barr; Ann M Geiger; Deborah Vollmer Dahlke; Bradley H Pollock; W Archie Bleyer Journal: Cancer Date: 2016-02-05 Impact factor: 6.860
Authors: Evelina M Miropolsky; Kevin Scott Baker; Mark Abbey-Lambertz; Karen Syrjala; Eric J Chow; Rachel Ceballos; Jason A Mendoza Journal: J Adolesc Young Adult Oncol Date: 2020-01-13 Impact factor: 2.223
Authors: H Irene Su; Brian Kwan; Brian W Whitcomb; Ksenya Shliakhsitsava; Andrew C Dietz; Shaylyn S Stark; Elena Martinez; Patrick M Sluss; Mary D Sammel; Loki Natarajan Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958
Authors: Pooja Rao; Joel E Segel; Lisa M McGregor; Eugene J Lengerich; Joseph J Drabick; Barbara Miller Journal: J Adolesc Young Adult Oncol Date: 2019-10-10 Impact factor: 2.223
Authors: Jin Mou; Effie L Bolieu; Bethann M Pflugeisen; Paul J Amoroso; Beth Devine; Laura-Mae Baldwin; Laura L Frank; Rebecca H Johnson Journal: J Adolesc Young Adult Oncol Date: 2019-02-20 Impact factor: 2.223
Authors: Amy M Berkman; J A Livingston; Kelly Merriman; Michelle Hildebrandt; Jian Wang; Seyedeh Dibaj; Jennifer McQuade; Nancy You; Anita Ying; Carlos Barcenas; Diane Bodurka; April DePombo; Hun Ju Lee; John de Groot; Michael Roth Journal: Cancer Date: 2020-06-02 Impact factor: 6.860
Authors: Alexandra M Psihogios; Lisa A Schwartz; Kylie B Ewing; Bryn Czerniecki; Leslie S Kersun; Ahna L H Pai; Janet A Deatrick; Lamia P Barakat Journal: J Adolesc Young Adult Oncol Date: 2020-05-11 Impact factor: 2.223
Authors: Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J Andrew Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-07-08 Impact factor: 4.254